Plus Therapeutics Appoints Eric J. Daniels as Chief Development Officer To Drive CNS Cancer Pipeline

Plus Therapeutics has announced the appointment of Eric J. Daniels, M.D., MBA, as its Chief Development Officer, effective April 20, 2026. The company, focused on precision diagnostics and radiopharmaceuticals for central nervous system cancers, aims to strengthen its leadership team with this strategic addition.

Dr. Daniels brings over 20 years of experience across clinical development, regulatory strategy, corporate operations, and business development. He most recently served as Chief Development Officer at Kiora Pharmaceuticals, where he managed the company’s entire development portfolio, including clinical, preclinical, and CMC activities, while working closely with executive leadership and the board to shape development strategy.

“Eric is a highly accomplished development leader with a proven ability to translate scientific innovation into clinically and commercially viable programs,” said Marc Hedrick, M.D., MBA, Plus Therapeutics President and Chief Executive Officer. “His experience building and advancing therapeutic pipelines, combined with his strategic and operational expertise, will be instrumental as we accelerate the advancement of REYOBIQ and our broader CNS oncology portfolio.”

In addition to his role at Kiora, Dr. Daniels has a strong entrepreneurial background. He co-founded Bayon Therapeutics and previously served as CEO of OccuRx, leading corporate strategy, clinical programs, and operations. Earlier in his career, he held senior leadership positions at Cytori Therapeutics, contributing to global clinical development initiatives and strategic partnerships.

“Plus Therapeutics is at a pivotal time in its promising development trajectory,” said Dr. Daniels. “The Company’s targeted radiotherapeutic platform is a highly differentiated approach to both targeting and treating CNS cancers, and I look forward to working with the team to advance REYOBIQ and deliver meaningful outcomes for patients and physicians.”

Dr. Daniels earned his medical degree from the David Geffen School of Medicine at UCLA and an MBA from the UCLA Anderson School of Management. He also holds a Bachelor of Science in Molecular and Cell Biology from the University of California Berkeley.

Also Read

Plus Therapeutics Secures FDA Orphan Drug Designation For REYOBIQ In Pediatric Brain Tumours